138 related articles for article (PubMed ID: 14527561)
1. Design of EGFR kinase inhibitors: a ligand-based approach and its confirmation with structure-based studies.
Vema A; Panigrahi SK; Rambabu G; Gopalakrishnan B; Sarma JA; Desiraju GR
Bioorg Med Chem; 2003 Oct; 11(21):4643-53. PubMed ID: 14527561
[TBL] [Abstract][Full Text] [Related]
2. 3D-QSAR and docking studies on 4-anilinoquinazoline and 4-anilinoquinoline epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors.
Assefa H; Kamath S; Buolamwini JK
J Comput Aided Mol Des; 2003 Aug; 17(8):475-93. PubMed ID: 14703120
[TBL] [Abstract][Full Text] [Related]
3. 3D-QSAR and molecular docking studies of 4-anilinoquinazoline derivatives: a rational approach to anticancer drug design.
Nandi S; Bagchi MC
Mol Divers; 2010 Feb; 14(1):27-38. PubMed ID: 19330460
[TBL] [Abstract][Full Text] [Related]
4. Achieving selectivity between highly homologous tyrosine kinases: a novel selective erbB2 inhibitor.
Bhattacharya SK; Cox ED; Kath JC; Mathiowetz AM; Morris J; Moyer JD; Pustilnik LR; Rafidi K; Richter DT; Su C; Wessel MD
Biochem Biophys Res Commun; 2003 Jul; 307(2):267-73. PubMed ID: 12859950
[TBL] [Abstract][Full Text] [Related]
5. Three-dimensional quantitative structure-activity relationship (3 D-QSAR) and docking studies on (benzothiazole-2-yl) acetonitrile derivatives as c-Jun N-terminal kinase-3 (JNK3) inhibitors.
Shaikh AR; Ismael M; Del Carpio CA; Tsuboi H; Koyama M; Endou A; Kubo M; Broclawik E; Miyamoto A
Bioorg Med Chem Lett; 2006 Nov; 16(22):5917-25. PubMed ID: 16989998
[TBL] [Abstract][Full Text] [Related]
6. Inhibitors of the epidermal growth factor receptor protein tyrosine kinase: a quantitative structure-activity relationship analysis.
Singh P; Kumar R
J Enzyme Inhib; 1998 Apr; 13(2):125-34. PubMed ID: 9629532
[TBL] [Abstract][Full Text] [Related]
7. 4-Anilino-6,7-dialkoxyquinoline-3-carbonitrile inhibitors of epidermal growth factor receptor kinase and their bioisosteric relationship to the 4-anilino-6,7-dialkoxyquinazoline inhibitors.
Wissner A; Berger DM; Boschelli DH; Floyd MB; Greenberger LM; Gruber BC; Johnson BD; Mamuya N; Nilakantan R; Reich MF; Shen R; Tsou HR; Upeslacis E; Wang YF; Wu B; Ye F; Zhang N
J Med Chem; 2000 Aug; 43(17):3244-56. PubMed ID: 10966743
[TBL] [Abstract][Full Text] [Related]
8. Specificity of alpha-cyano-beta-hydroxy-beta-methyl-n-[4-(trifluoromethoxy)phe nyl]-propenamide as an inhibitor of the epidermal growth factor receptor tyrosine kinase.
Ghosh S; Zheng Y; Jun X; Mahajan S; Mao C; Sudbeck EA; Uckun FM
Clin Cancer Res; 1999 Dec; 5(12):4264-72. PubMed ID: 10632369
[TBL] [Abstract][Full Text] [Related]
9. Allosteric inhibition of fructose-1,6-bisphosphatase by anilinoquinazolines.
Wright SW; Hageman DL; McClure LD; Carlo AA; Treadway JL; Mathiowetz AM; Withka JM; Bauer PH
Bioorg Med Chem Lett; 2001 Jan; 11(1):17-21. PubMed ID: 11140724
[TBL] [Abstract][Full Text] [Related]
10. Mapping the binding site of a large set of quinazoline type EGF-R inhibitors using molecular field analyses and molecular docking studies.
Hou T; Zhu L; Chen L; Xu X
J Chem Inf Comput Sci; 2003; 43(1):273-87. PubMed ID: 12546563
[TBL] [Abstract][Full Text] [Related]
11. In silico QSAR studies of anilinoquinolines as EGFR inhibitors.
Pasha FA; Muddassar M; Srivastava AK; Cho SJ
J Mol Model; 2010 Feb; 16(2):263-77. PubMed ID: 19590909
[TBL] [Abstract][Full Text] [Related]
12. 4-anilino-3-quinolinecarbonitriles: an emerging class of kinase inhibitors.
Boschelli DH
Curr Top Med Chem; 2002 Sep; 2(9):1051-63. PubMed ID: 12171571
[TBL] [Abstract][Full Text] [Related]
13. Enantioselective inhibition of the epidermal growth factor receptor tyrosine kinase by 4-(alpha-phenethylamino)quinazolines.
Bridges AJ; Cody DR; Zhou H; McMichael A; Fry DW
Bioorg Med Chem; 1995 Dec; 3(12):1651-6. PubMed ID: 8770389
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and evaluation of novel hybrids between 4-anilinoquinazolines and substituted triazoles as potent cytotoxic agents.
Le-Nhat-Thuy G; Dinh TV; Pham-The H; Nguyen Quang H; Nguyen Thi N; Dang Thi TA; Hoang Thi P; Le Thi TA; Nguyen HT; Nguyen Thanh P; Le Duc T; Nguyen TV
Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3741-3747. PubMed ID: 30337229
[TBL] [Abstract][Full Text] [Related]
15. Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with the ATP binding site.
Arteaga CL; Ramsey TT; Shawver LK; Guyer CA
J Biol Chem; 1997 Sep; 272(37):23247-54. PubMed ID: 9287333
[TBL] [Abstract][Full Text] [Related]
16. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells.
Wood ER; Truesdale AT; McDonald OB; Yuan D; Hassell A; Dickerson SH; Ellis B; Pennisi C; Horne E; Lackey K; Alligood KJ; Rusnak DW; Gilmer TM; Shewchuk L
Cancer Res; 2004 Sep; 64(18):6652-9. PubMed ID: 15374980
[TBL] [Abstract][Full Text] [Related]
17. Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor.
Bridges AJ; Zhou H; Cody DR; Rewcastle GW; McMichael A; Showalter HD; Fry DW; Kraker AJ; Denny WA
J Med Chem; 1996 Jan; 39(1):267-76. PubMed ID: 8568816
[TBL] [Abstract][Full Text] [Related]
18. Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor.
Smaill JB; Showalter HD; Zhou H; Bridges AJ; McNamara DJ; Fry DW; Nelson JM; Sherwood V; Vincent PW; Roberts BJ; Elliott WL; Denny WA
J Med Chem; 2001 Feb; 44(3):429-40. PubMed ID: 11462982
[TBL] [Abstract][Full Text] [Related]
19. QSAR of aromatic substances: EGFR inhibitory activity of quinazoline analogues.
Deeb O; Clare BW
J Enzyme Inhib Med Chem; 2008 Dec; 23(6):763-75. PubMed ID: 18608750
[TBL] [Abstract][Full Text] [Related]
20. Structure-activity relationships for 4-anilinoquinazolines as potent inhibitors at the ATP binding site of the epidermal growth factor receptor in vitro.
Denny WA; Rewcastle GW; Bridges AJ; Fry DW; Kraker AJ
Clin Exp Pharmacol Physiol; 1996 May; 23(5):424-7. PubMed ID: 8713682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
